| » View all news titles
|| » View titles this week
||» View titles this month
Most children with acute lymphoblastic leukemia (ALL) can be cured, but the prognosis is dismal for about 20 percent of patients who relapse after treatment.
Now a new study from researchers at Columbia University’s Herbert Irving Comprehensive Cancer Center has found that a mutation that leads to relapse in many ALL patients also causes a weakness that could be exploited to kill the cancer cells in patients experiencing relapse.